Nektar Therapeutics - Company Profile
Powered by 
All the data and insights you need on Nektar Therapeutics in one report.
$295
- Save hours of research time and resources with
our up-to-date Nektar Therapeutics Strategy Report
- Understand Nektar Therapeutics position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
The following section provides information on Nektar Therapeutics’s senior management, executives, CEO and key decision makers and their roles in the organization. For more insight into Nektar Therapeutics's management and employees, unlock the full data with our company analytics monitoring tool.
Executives
Robert B. Chess
Chairman Executive BoardMr. Rober B. Chess has been the Chairman of Nektar Therapeutics since January 2007. Prior to this, he served as a Director of the company. Mr. Chess also served as the Acting President and the Chief Executive Officer of Nektar, Chairman of OPX Biotechnologies. Prior to that, he served as the Acting President and the Chief Executive Officer from March 2006 until January 2007, Mr. Chess also served as the President of Penederm, Inc. Currently, he is also the Chairman of Biota Technology.
Howard W. Robin
Director; Chief Executive Officer; President Executive BoardMr. Howard W. Robin has been the President, Chief Executive Officer and Director of the company since January 2007. Prior to this, he served as the Chief Executive Officer, President and Director of Sirna Therapeutics, Inc. Mr. Robin served as the Chief Operating Officer, President and as a Director of the company from January 2001 to June 2001 at Sirna. He also served as the Corporate Vice President and General Manager, Vice President of Finance and Business Development and Chief Financial Officer at Berlex.
Sandra Gardiner
Chief Financial Officer Senior ManagementMs. Sandra Gardiner has been the Chief Financial Officer of the company since 2023. Prior to this, she served as the Chief Financial Officer, Executive Vice President of Finance and Administration, Secretary and Treasurer of Pulse Biosciences, Inc. She is also a Partner at FLG Partners.
Mark A. Wilson
Chief Legal Officer; Senior Vice President Senior ManagementMr. Mark A. Wilson has been the Chief Legal Officer and Senior Vice President of the company since 2022. Previously, he served as the General Counsel and Vice President of Intellectual Property division of the company. Previously, he also served as an Associate at Reed & Associates.
Mary Tagliaferri, M.D.
Chief Medical Officer Senior ManagementMs. Mary Tagliaferri is the Chief Medical Officer of the company. Prior to that, she served as the Clinical and Regulatory Consultant at InterMune. Previously, she also served as Chief Medical Officer at KangLaiTe USA and President and Chief Medical Officer at BioNovo.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer